These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35656996)

  • 1. Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke.
    Zhou LW; Kraler L; de Havenon A; Lansberg MG
    J Am Heart Assoc; 2022 Jun; 11(11):e024992. PubMed ID: 35656996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke.
    Pan Y; Wang A; Liu G; Zhao X; Meng X; Zhao K; Liu L; Wang C; Johnston SC; Wang Y; Wang Y;
    J Am Heart Assoc; 2014 Jun; 3(3):e000912. PubMed ID: 24904018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
    Schleinitz MD; Heidenreich PA
    Ann Intern Med; 2005 Feb; 142(4):251-9. PubMed ID: 15710958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective.
    Micieli A; Singh N; Jahn B; Siebert U; Menon BK; Demchuk AM
    Int J Stroke; 2023 Apr; 18(4):416-425. PubMed ID: 35739635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial.
    Hoshino H; Toyoda K; Omae K; Ishida N; Uchiyama S; Kimura K; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K; Matsumoto M; Tominaga T; Tomimoto H; Terayama Y; Yasuda S; Yamaguchi T;
    Stroke; 2021 Nov; 52(11):3430-3439. PubMed ID: 34404237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of CYP2C19 genotype-guided antiplatelet therapy for patients with acute minor ischemic stroke and high-risk transient ischemic attack in China.
    Zhang Z; Bao Y; Gu Y; Zhang M; Li X
    Br J Clin Pharmacol; 2024 Feb; 90(2):483-492. PubMed ID: 37795861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
    Sarasin FP; Gaspoz JM; Bounameaux H
    Arch Intern Med; 2000 Oct; 160(18):2773-8. PubMed ID: 11025787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
    Zhang L; Lin Z; Yin H; Liu J; Xuan J
    Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
    Jiang M; You JHS
    Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke.
    Lee YJ; Je NK
    Eur J Clin Pharmacol; 2023 Aug; 79(8):1107-1116. PubMed ID: 37310478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
    Nishiyama Y; Kimura K; Otsuka T; Toyoda K; Uchiyama S; Hoshino H; Sakai N; Okada Y; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Minematsu K; Matsumoto M; Tominaga T; Tomimoto H; Terayama Y; Yasuda S; Yamaguchi T;
    Stroke; 2023 Mar; 54(3):697-705. PubMed ID: 36734235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China.
    Lin Z; Zhang L; Yang X; Liu L; Xuan J
    J Med Econ; 2020 Jun; 23(6):659-666. PubMed ID: 31999196
    [No Abstract]   [Full Text] [Related]  

  • 19. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet Therapy After Noncardioembolic Stroke.
    Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
    Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.